James L. Rubenstein

James L. Rubenstein

Hematology Oncology

400 Parnassus Ave.
Fourth Floor
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 62 publications

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma.

YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

CGE26-139: Genomic Signatures of CNS and Systemic Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Profiled With Next Generation Sequencing (NGS).

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 01, 2026

YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma.

YIA26-002: Automated Segmentation and Radiogenomic Analysis of Primary CNS Lymphoma.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

Small molecule protein assembly modulators with pan-cancer therapeutic efficacy.

Small molecule protein assembly modulators with pan-cancer therapeutic efficacy.

Journal: Open biology

Published: December 17, 2024

Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.

Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.

Journal: Blood advances

Published: August 06, 2024

Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors.

Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors.

Journal: Journal of hematopathology

Published: July 30, 2024

Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.

Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.

Journal: Neuro-oncology

Published: April 10, 2024

Utility of PD-1, PD-L1, and IDO-1 Stains in Ocular Extranodal Marginal Zone Lymphoma (MZL) and Diffuse Large B-cell Lymphoma (DLBCL).

Utility of PD-1, PD-L1, and IDO-1 Stains in Ocular Extranodal Marginal Zone Lymphoma (MZL) and Diffuse Large B-cell Lymphoma (DLBCL).

Journal: Applied immunohistochemistry & molecular morphology : AIMM

Published: March 01, 2024

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.

Journal: Blood advances

Published: September 11, 2023

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.

Journal: Leukemia & lymphoma

Published: March 24, 2023

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Journal: American journal of hematology

Published: February 27, 2023

Showing 1-12 of 62

Last Updated: 09/26/2026